

27 March 2024

Clinical Trials in Oncology

I am reaching out to gather crucial information regarding the pre- and current post-BREXIT clinical trials landscape in Oncology on a nationwide basis in the UK. Your expertise and insight from your current NHS hospital Trust that you represent, are invaluable in enhancing our understanding of the trends and challenges in this field, so that appropriate recommendations could be made.

Before completing this survey, kindly check to ensure that your hospital(s) provide(s) systemic therapy for solid cancer (i.e. initiation of SACT and follow up of Oncology patients) in adults. If so, please proceed with this survey.

If your hospital does not provide systemic therapy for solid cancers, then please do not complete this survey and instead e-mail back to notify us and we will update our records accordingly.

Furthermore, we advise that whoever is designated to complete this survey should be in charge of, lead or co-ordinate the solid cancer, thus only Oncology (i.e. NOT haematological malignancies, not haem-onc) clinical trials department at your NHS hospital. Questions should be answered on behalf of the organisation.

In relation to this survey, we only aim to obtain data regarding systemic anti-cancer therapies (SACT) as investigational medicinal products (IMP). Examples of such therapies include chemotherapy, cellular therapies, biologics, hormonal therapy, targeted therapy, immunotherapy and other. This survey specifically enquires about interventional studies (e.g. studying the safety and/or efficacy of novel treatments).

In the case of multi-phase trials, indicate the lower phase number. We request information from the following hospitals:

We are unable to provide the information requested in your Survey Monkey as it is not held on a database and would require a manual trawl through records.

We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

It is therefore exempt from release under Section 12 – Fees Limits.